Localization of Pharmaceutical Raw Materials
and Joint Development of Peptide Ingredients for Obesity Treatments
Donggu Bio Pharmaceutical announced on the 10th that it signed a strategic partnership with Gukjeon Pharm on the 7th to localize pharmaceutical raw materials in South Korea.
The partnership aims to jointly develop peptide-based obesity treatment raw materials (non-reimbursed raw materials) and to jointly sell them in domestic and global markets. It is expected to contribute to strengthening the competitiveness of the domestic raw pharmaceutical ingredients (Active Pharmaceutical Ingredients, API) industry.
Based on its solid position in the dermatology and urology specialty pharmaceutical fields and its strength in discovering new growth engines, Donggu Bio Pharmaceutical will expand its pharmaceutical portfolio and enter the advanced biopharmaceutical market through this partnership.
In the current pharmaceutical industry environment, where dependence on overseas raw materials is high for major raw pharmaceutical ingredients, Donggu Bio Pharmaceutical and Gukjeon Pharm will focus on establishing a stable supply chain and securing cost competitiveness through localization of raw materials. They will maximize synergy by combining Gukjeon Pharm’s capabilities in raw pharmaceutical ingredient and intermediate development with Donggu Bio Pharmaceutical’s know-how in drug development and commercialization.
They plan to focus on developing peptide raw materials for obesity treatments, which have high growth potential as innovative drugs in various therapeutic areas. Through collaboration, they will develop domestically produced raw materials for obesity treatment that can replace previously overseas-dependent peptide pharmaceuticals and enter the global market.
They plan to strengthen joint research and development (R&D) and production cooperation, secure domestic and global certifications through optimized production process establishment and quality enhancement, and increase sales synergy by jointly entering domestic and international markets with the developed raw materials and pharmaceuticals.
Utilizing Donggu Bio Pharmaceutical’s established overseas network, they agreed to cooperate so that raw materials developed by Gukjeon Pharm can be supplied to global pharmaceutical companies. By leveraging each company’s strengths, they aim to maximize synergy, increase the self-sufficiency of raw materials in the domestic pharmaceutical industry, and secure competitiveness in overseas markets.
Donggu Bio Pharmaceutical Chairman Jo Yong-jun explained, "This partnership with Gukjeon Pharm is a meaningful opportunity to solve the important task of localizing biopharmaceutical raw materials while diversifying our product portfolio." He added, "We will actively nurture this business to leap forward as a total healthcare leading company."
Gukjeon Pharm CEO Hong Jong-ho said, "We will pioneer new markets through the development of peptide raw materials for obesity treatments and contribute to the growth of the domestic pharmaceutical industry." He added, "We will further strengthen R&D and production capabilities through cooperation with Donggu Bio Pharmaceutical."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
